Literature DB >> 20890676

Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis.

James H Soper1, Victoria Kehm, Christopher G Burd, Vytas A Bankaitis, Virginia M-Y Lee.   

Abstract

Parkinson's disease is the most common neurodegenerative movement disorder. α-Synuclein is a small synaptic protein that has been linked to familial Parkinson's disease (PD) and is also the primary component of Lewy bodies, the hallmark neuropathology found in the brain of sporadic and familial PD patients. The function of α-synuclein is currently unknown, although it has been implicated in the regulation of synaptic vesicle localization or fusion. Recently, overexpression of α-synuclein was shown to cause cytoplasmic vesicle accumulation in a yeast model of α-synuclein toxicity, but the exact role α-synuclein played in mediating this vesicle aggregation is unclear. Here, we show that α-synuclein induces aggregation of many yeast Rab GTPase proteins, that α-synuclein aggregation is enhanced in yeast mutants that produce high levels of acidic phospholipids, and that α-synuclein colocalizes with yeast membranes that are enriched for phosphatidic acid. Significantly, we demonstrate that α-synuclein expression induces vulnerability to perturbations of Ypt6 and other proteins involved in retrograde endosome-Golgi transport, linking a specific trafficking defect to α-synuclein phospholipid binding. These data suggest new pathogenic mechanisms for α-synuclein neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890676      PMCID: PMC3147281          DOI: 10.1007/s12031-010-9455-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  91 in total

1.  The exocyst is an effector for Sec4p, targeting secretory vesicles to sites of exocytosis.

Authors:  W Guo; D Roth; C Walch-Solimena; P Novick
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

2.  Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications.

Authors:  C B Brachmann; A Davies; G J Cost; E Caputo; J Li; P Hieter; J D Boeke
Journal:  Yeast       Date:  1998-01-30       Impact factor: 3.239

3.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.

Authors:  S J Wood; J Wypych; S Steavenson; J C Louis; M Citron; A L Biere
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

4.  The GRIP domain - a novel Golgi-targeting domain found in several coiled-coil proteins.

Authors:  S Munro; B J Nichols
Journal:  Curr Biol       Date:  1999-04-08       Impact factor: 10.834

5.  Primary structure and biochemical characterization of yeast GTPase-activating proteins with substrate preference for the transport GTPase Ypt7p.

Authors:  P Vollmer; E Will; D Scheglmann; M Strom; D Gallwitz
Journal:  Eur J Biochem       Date:  1999-02

6.  Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes.

Authors:  W S Davidson; A Jonas; D F Clayton; J M George
Journal:  J Biol Chem       Date:  1998-04-17       Impact factor: 5.157

7.  Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro.

Authors:  B I Giasson; K Uryu; J Q Trojanowski; V M Lee
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

8.  Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.

Authors:  K A Conway; J D Harper; P T Lansbury
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

9.  Phospholipase D activity is required for suppression of yeast phosphatidylinositol transfer protein defects.

Authors:  Z Xie; M Fang; M P Rivas; A J Faulkner; P C Sternweis; J A Engebrecht; V A Bankaitis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

10.  Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.

Authors:  P H Jensen; M S Nielsen; R Jakes; C G Dotti; M Goedert
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

View more
  38 in total

1.  Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.

Authors:  Doris Petroi; Blagovesta Popova; Naimeh Taheri-Talesh; Stefan Irniger; Hedieh Shahpasandzadeh; Markus Zweckstetter; Tiago F Outeiro; Gerhard H Braus
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

Review 2.  The physiological role of α-synuclein and its relationship to Parkinson's Disease.

Authors:  David Sulzer; Robert H Edwards
Journal:  J Neurochem       Date:  2019-07-28       Impact factor: 5.372

3.  Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity.

Authors:  Daniel Ysselstein; Mehul Joshi; Vartika Mishra; Amy M Griggs; Josephat M Asiago; George P McCabe; Lia A Stanciu; Carol Beth Post; Jean-Christophe Rochet
Journal:  Neurobiol Dis       Date:  2015-04-27       Impact factor: 5.996

Review 4.  Cell Biology and Pathophysiology of α-Synuclein.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

5.  From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies.

Authors:  Jeff S Piotrowski; Daniel F Tardiff
Journal:  Methods Mol Biol       Date:  2019

6.  Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways.

Authors:  Vikram Khurana; Jian Peng; Chee Yeun Chung; Pavan K Auluck; Saranna Fanning; Daniel F Tardiff; Theresa Bartels; Martina Koeva; Stephen W Eichhorn; Hadar Benyamini; Yali Lou; Andy Nutter-Upham; Valeriya Baru; Yelena Freyzon; Nurcan Tuncbag; Michael Costanzo; Bryan-Joseph San Luis; David C Schöndorf; M Inmaculada Barrasa; Sepehr Ehsani; Neville Sanjana; Quan Zhong; Thomas Gasser; David P Bartel; Marc Vidal; Michela Deleidi; Charles Boone; Ernest Fraenkel; Bonnie Berger; Susan Lindquist
Journal:  Cell Syst       Date:  2017-01-25       Impact factor: 10.304

Review 7.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

8.  Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy.

Authors:  Selcuk A Tanik; Christine E Schultheiss; Laura A Volpicelli-Daley; Kurt R Brunden; Virginia M Y Lee
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

Review 9.  Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology.

Authors:  Sibylle E Eisbach; Tiago F Outeiro
Journal:  J Mol Med (Berl)       Date:  2013-04-25       Impact factor: 4.599

Review 10.  Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets?

Authors:  Tian-Fang Jiang; Sheng-Di Chen
Journal:  Neurosci Bull       Date:  2012-09-08       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.